Finerenone helps slow kidney disease in patients without diabetes
New global studies indicate that the drug finerenone can effectively slow the progression of chronic kidney disease in patients who do not have diabetes. By blocking inflammation and scarring, the medication offers a new treatment pathway for those at risk of kidney failure.
Why it matters
This finding expands the therapeutic options for a widespread chronic condition, potentially improving long-term health outcomes for millions.
In chronic kidney disease , the kidneys gradually lose their ability to filter waste from the blood. While diabetes is one of its leading causes, many patients develop the condition because of high blood pressure, autoimmune disorders or other conditions that damage the kidney’s filtering units.
Reporting based on peer-reviewed medical journals and clinical trial results.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in